Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes

International Journal of Neuropsychopharmacology

Volumn 17, Issue 6, 2014, Pages 929-943

  Gardiner, Erin ^a,b,c   Carroll, Adam ^a,b,c   Tooney, Paul A ^a,b,c   Cairns, Murray J ^a,b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Schizophrenia Research Institute   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antipsychotic; Lymphocyte; MiRNA; mRNA; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; MICRORNA; NEUROLEPTIC AGENT;

ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERACTIONS WITH RNA; JURKAT CELL LINE; METABOLIC DISORDER; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NEUROLOGIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION; COMPARATIVE STUDY; CULTURE TECHNIQUE; DRUG EFFECTS; GENE EXPRESSION; METABOLISM;

ANTIPSYCHOTIC AGENTS; CELL CULTURE TECHNIQUES; CHLORPROMAZINE; CLOZAPINE; GENE EXPRESSION; HALOPERIDOL; HUMANS; JURKAT CELLS; MICROARRAY ANALYSIS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84899925456     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001752     Document Type: Article

References (103)

1. Agid O, Seeman P, Kapur S. (2006) The 'delayed onset' of antipsychotic action-An idea whose time has come and gone. J Psychiatry Neurosci 31:93-100.
2. Akgul C, Moulding DA, Edwards SW. (2001) Molecular control of neutrophil apoptosis. FEBS letters 487:318-322.
3. Akterin S, Cowburn RF, Miranda-Vizuete A, Jimenez A, Bogdanovic N, Winblad B, Cedazo-Minguez A. (2006) Involvement of glutaredoxin-1 and thioredoxin-1 in beta-Amyloid toxicity and Alzheimer's disease. Cell Death Differ 13:1454-1465.
4. Andreassen OA, Jorgensen HA. (2000) Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 61:525-541.
5. Bennett RL, Blalock WL, Choi EJ, Lee YJ, Zhang Y, Zhou L, Oh SP, May WS. (2008) RAX is required for fly neuronal development and mouse embryogenesis. Mech Dev 125:777-785.
6. Beveridge NJ, Cairns MJ. (2012) MicroRNA dysregulation in schizophrenia. Neurobiol Dis 46:263-271.
7. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I, Cairns MJ. (2008) Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17:1156-1168.
8. Beveridge NJ, Tooney PA, Carroll AP, Tran N, Cairns MJ. (2009) Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal 21:1837-1845.
9. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. (2010) Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 15:1176-1189.
10. Beveridge NJ, Santarelli DM, Wang X, Tooney PA, Webster MJ, Weickert CS, Cairns MJ. (2013) Maturation of the human dorsolateral prefrontal cortex coincides with a dynamic shift in microRNA expression. Schizophr Bull. Jan 31. [Epub ahead of print.]
11. Bragg DC, Armata IA, Nery FC, Breakefield XO, Sharma N. (2011) Molecular pathways in dystonia. Neurobiol Dis 42:136-147.
12. Camargos S, Scholz S, Simon-Sanchez J, Paisan-Ruiz C, Lewis P, Hernandez D, Ding J, Gibbs JR, Cookson MR, Bras J, Guerreiro R, Oliveira CR, Lees A, Hardy J, Cardoso F, Singleton AB. (2008) DYT16, a novel young-onset dystonia-parkinsonism disorder: Identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 7:207-215.
13. Canfran-Duque A, Casado ME, Pastor O, Sanchez-Wandelmer J, de la Pena G, Lerma M, Mariscal P, Bracher F, Lasuncion MA, Busto R. (2013) Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 54:310-324.
14. Carpenter WT, Koenig JI. (2008) The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 33:2061-2079.
15. Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI, Kyriazopoulou VE, Habeos IG. (2012) Differential expression of microRNAs in adipose tissue after long-Term high-fat diet-induced obesity in mice. PLoS ONE 7: E34872.
16. Chen ML, Tsai TC, Wang LK, Lin YY, Tsai YM, Lee MC, Tsai FM. (2012) Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-gamma production in peripheral blood mononuclear cells. Immunopharmacol Immunotoxicol 34:686-694.
17. Cho CH, Lee HJ. (2012) Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence. Prog Neuro-Psychopharmacol Biolog Psychiatry 46:207-213.
18. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, Saporiti F, Meloni F, Marino F, Lecchini S. (2007) Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109:632-642.
19. Davis JM, Chen N, Glick ID. (2003) A meta-Analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564.
20. Dinan TG. (2010) MicroRNAs as a target for novel antipsychotics: A systematic review of an emerging field. Int J Neuropsychopharmacol 13:395-404.
21. Diwakar L, Kenchappa RS, Annepu J, Ravindranath V. (2007) Downregulation of glutaredoxin but not glutathione loss leads to mitochondrial dysfunction in female mice CNS: Implications in excitotoxicity. Neurochem Int 51:37-46.
22. Donze O, Deng J, Curran J, Sladek R, Picard D, Sonenberg N. (2004) The protein kinase PKR: A molecular clock that sequentially activates survival and death programs. EMBO J 23:564-571.
23. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20:532-545.
24. Duncan CE, Chetcuti AF, Schofield PR. (2008) Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. Psychiatr Genet 18:226-239.
25. Eisen MB, Spellman PT, Brown PO, Botstein D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868.
26. Essali A, Al-Haj Haasan N, Li C, Rathbone J. (2009) Clozapine vs typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. Jan 21;(1): CD000059.
27. Fatemi SH, Folsom TD, Reutiman TJ, Novak J, Engel RH. (2012) Comparative gene expression study of the chronic exposure to clozapine and haloperidol in rat frontal cortex. Schizophr Res 134:211-218.
28. Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, Kolb-Bachofen V, Klimke A. (2005) Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 25:419-426.
29. Felberbaum-Corti M, Morel E, Cavalli V, Vilbois F, Gruenberg J. (2007) The redox sensor TXNL1 plays a regulatory role in fluid phase endocytosis. PLoS ONE 2:e1144.
30. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM. (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: A novel mechanism of action? Pharmacogenomics J 5:298-304.
31. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, Cairns M, Weickert CS. (2012) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry.
32. Flanagan RJ, Dunk L. (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 23(Suppl. 1):27-41.
33. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA, Cairns MJ. (2012) Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-Associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 17:827-840.
34. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B, Scott RJ, Tooney PA. (2013) Gene expression analysis reveals schizophrenia-Associated dysregulation of immune pathways in peripheral blood mononuclear cells. J Psychiatr Res 47:425-437.
35. Gardner I, Zahid N, MacCrimmon D, Uetrecht JP. (1998) A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 53:991-998.
36. Heiser P, Enning F, Krieg JC, Vedder H. (2007) Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro. J Psychopharmacol 21:851-856.
37. Himmerich H, Schonherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U. (2011) Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45:1358-1365.
38. Husain Z, Almeciga I, Delgado JC, Clavijo OP, Castro JE, Belalcazar V, Pinto C, Zuniga J, Romero V, Yunis EJ. (2006) Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol 214:326-334.
39. Hwang Y, Kim J, Shin JY, Kim JI, Seo JS, Webster MJ, Lee D, Kim S. (2013) Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 3:e321.
40. Iverson S, Kautiainen A, Ip J, Uetrecht JP. (2010) Effect of clozapine on neutrophil kinetics in rabbits. Chem Res Toxicol 23:1184-1191.
41. Jain T, Bhandari A, Ram V, Sharma S, Parakh M, Parakh MC. (2011) Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients. Clin Biochem 44:675-680.
42. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. (2005) Evidence for onset of antipsychotic effects within the first 24 hs of treatment. Am J Psychiatry 162:939-946.
43. Kennell JA, Gerin I, MacDougald OA, Cadigan KM. (2008) The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad Sci USA 105:15417-15422.
44. Kinon BJ, Chen L, Stauffer VL, Sniadecki J, Ascher-Svanum H, Kollack-Walker S, Jacob J, Kapur S. (2010) Early onset of antipsychotic action in schizophrenia: Evaluating the possibility of shorter acute efficacy trials. J Clin Psychopharmacol 30:286-289.
45. Lahdelma L, Oja S, Korhonen M, Andersson LC. (2010) Clozapine is cytotoxic to primary cultures of human bone marrow mesenchymal stromal cells. J Clin Psychopharmacol 30:461-463.
46. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC, Huang YH, Hsiao PC, Hsiao CK, Liu CM, Yang PC, Hwu HG, Chen WJ. (2011) MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS ONE 6: E21635.
47. Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE, Edenberg HJ, Kuczenski R, Geyer MA, Nurnberger JI Jr., Faraone SV, Tsuang MT, Niculescu AB. (2007) Towards understanding the schizophrenia code: An expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 144B:129-158.
48. Lee ES, Yoon CH, Kim YS, Bae YS. (2007) The double-strand RNA-dependent protein kinase PKR plays a significant role in a sustained ER stress-induced apoptosis. FEBS letters 581:4325-4332.
49. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM. (2009) A meta-Analysis of head-To-head comparisons of secondgeneration antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163.
50. Levite M. (2008) Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 8:460-471.
51. Lezoualc'h F, Rupprecht R, Holsboer F, Behl C. (1996) Bcl-2 prevents hippocampal cell death induced by the neuroleptic drug haloperidol. Brain Res 738:176-179.
52. Li M, Fletcher PJ, Kapur S. (2007) Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272.
53. Lohr JB, Kuczenski R, Niculescu AB. (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17:47-62.
54. MacDonald ML, Eaton ME, Dudman JT, Konradi C. (2005) Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 57:1041-1051.
55. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, Falkai P, Schmitt A, Turck CW. (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatric Res 44:1176-1189.
56. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. (2007) Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46:359-388.
57. Mehler-Wex C, Grunblatt E, Zeiske S, Gille G, Rausch D, Warnke A, Gerlach M. (2006) Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: Implications for body weight changes. J Neural Transm 113:1383-1393.
58. Meltzer HY, Huang M. (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177-197.
59. Miljevic C, Nikolic M, Nikolic-Kokic A, Jones DR, Niketic V, Lecic-Tosevski D, Spasic MB. (2010) Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-Term clozapine-Treated schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 34:303-307.
60. Miller G. (2012) Mysteries of the brain. Why is mental illness so hard to treat? Science. (New York, NY) 338:32-33.
61. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. (2005) Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104.
62. Mor E, Kano SI, Colantuoni C, Sawa A, Navon R, Shomron N. (2013) MicroRNA-382 expression is elevated in the olfactory neuroepithelium of schizophrenia patients. Neurobiol Dis 55C:1-10.
63. Newcomer JW. (2007) Antipsychotic medications: Metabolic and cardiovascular risk. J Clin Psychiatry 68(Suppl. 4):8-13.
64. Nielsen J, Damkier P, Lublin H, Taylor D. (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411-422.
65. Nooijen PM, Carvalho F, Flanagan RJ. (2011) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol 26:112-119.
66. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. (1999) Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 96:14943-14948.
67. Patel CV, Handy I, Goldsmith T, Patel RC. (2000) PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-Activated protein kinase, PKR. The J Biol Chem 275:37993-37998.
68. Pereira A, Dean B. (2006) Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: A potential in vitro system for the study of agranulocytosis. Biochem Pharmacol 72:783-793.
69. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J, Hammond SM. (2007) microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8:R27.
70. Polymeropoulos MH, Licamele L, Volpi S, Mack K, Mitkus SN, Carstea ED, Getoor L, Thompson A, Lavedan C. (2009) Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr Res 108:134-142.
71. Post A, Rucker M, Ohl F, Uhr M, Holsboer F, Almeida OF, Michaelidis TM. (2002) Mechanisms underlying the protective potential of alpha-Tocopherol. (vitamin E) against haloperidol-Associated neurotoxicity. Neuropsychopharmacology 26:397-407.
72. Raedler TJ, Schreiner A, Naber D, Wiedemann K. (2007) Early onset of treatment effects with oral risperidone. BMC Psychiatry 7:4.
73. Rizig MA, McQuillin A, Ng A, Robinson M, Harrison A, Zvelebil M, Hunt SP, Gurling HM. (2012) A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia. J Psychopharmacol 26:1218-1230.
74. Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. (2012) Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far? Schizophr Res 140:204-213.
75. Rolland SG, Conradt B. (2010) New role of the BCL2 family of proteins in the regulation of mitochondrial dynamics. Curr Opin Cell Biol 22:852-858.
76. Sabens Liedhegner EA, Gao XH, Mieyal JJ. (2012) Mechanisms of altered redox regulation in neurodegenerative diseases-focus on S-glutathionylation. Antioxid Redox Signal 16:543-566.
77. Saeed U, Durgadoss L, Valli RK, Joshi DC, Joshi PG, Ravindranath V. (2008) Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: Implication in neurodegenerative diseases. PLoS ONE 3:e2459.
78. Saldanha AJ. (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics. (Oxford, England) 20:3246-3248.
79. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ. (2011) Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biological Psychiatry 69:180-187.
80. Santarelli DM, Liu B, Duncan CE, Beveridge NJ, Tooney PA, Schofield PR, Cairns MJ. (2013) Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine. Psychopharmacology. (Berl) 227:67-78.
81. Schneider U, Schwenk HU, Bornkamm G. (1977) Characterization of EBV-genome negative 'null' and 'T' cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19:621-626.
82. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology. (Berl) 124:57-73.
83. Sedvall G, Farde L, Persson A, Wiesel FA. (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43:995-1005.
84. Seeman P. (2010) Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 4:56-73.
85. Seibler P, Djarmati A, Langpap B, Hagenah J, Schmidt A, Bruggemann N, Siebner H, Jabusch HC, Altenmuller E, Munchau A, Lohmann K, Klein C. (2008) A heterozygous frameshift mutation in PRKRA. (DYT16) associated with generalised dystonia in a German patient. Lancet Neurol 7:380-381.
86. Shi W, Du J, Qi Y, Liang G, Wang T, Li S, Xie S, Zeshan B, Xiao Z. (2012) Aberrant expression of serum miRNAs in schizophrenia. J Psychiatric Res 46:198-204.
87. Singh M, Patel RC. (2012) Increased interaction between PACT molecules in response to stress signals is required for PKR activation. J Cell Biochem 113:2754-2764.
88. Sondhi S, Castellano JM, Chong VZ, Rogoza RM, Skoblenick KJ, Dyck BA, Gabriele J, Thomas N, Ki K, Pristupa ZB, Singh AN, MacCrimmon D, Voruganti P, Foster J, Mishra RK. (2006) cDNA array reveals increased expression of glucosedependent insulinotropic polypeptide following chronic clozapine treatment: Role in atypical antipsychotic drug-induced adverse metabolic effects. Pharmacogenomics J 6:131-140.
89. Stroher E, Millar AH. (2012) The biological roles of glutaredoxins. Biochem J 446:333-348.
90. Taylor DM, Young C, Paton C. (2003) Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review. J Clin Psychiatry 64:30-34.
91. Taylor SS, Haste NM, Ghosh G. (2005) PKR and eIF2alpha: Integration of kinase dimerization, activation, and substrate docking. Cell 122:823-825.
92. Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL. (2007) Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: Role of oxidative stress pathway genes. Schizophr Res 92:278-279.
93. Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D, Sutcliffe JG. (2003) Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 8:983-993, 950.
94. Tusher VG, Tibshirani R, Chu G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121.
95. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. (2002) Accurate normalization of real-Time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
96. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. (2003) Atypical antipsychotics attenuate neurotoxicity of beta-Amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J Neurosci Res 74:942-947.
97. Weidenhofer J, Scott RJ, Tooney PA. (2009) Investigation of the expression of genes affecting cytomatrix active zone function in the amygdala in schizophrenia: Effects of antipsychotic drugs. J Psychiatr Res 43:282-290.
98. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, Park BK. (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375-1382.
99. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. (2000) Induction of metabolism-dependent and-independent neutrophil apoptosis by clozapine. Mol Pharmacol 58:207-216.
100. Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. (2003) Clozapine as a first treatment for schizophrenia. Am J Psychiatry 160:1514-1516.
101. Wong J, Duncan CE, Beveridge NJ, Webster MJ, Cairns MJ, Weickert CS. (2013) Expression of NPAS3 in the human cortex and evidence of its posttranscriptional regulation by miR-17 during development, with implications for schizophrenia. Schizophr Bull 39:396-306.
102. Wright C, Turner JA, Calhoun VD, Perrone-Bizzozero N. (2013) Potential impact of miR-137 and its targets in schizophrenia. Front Genet 4:58.
103. Xu J, Sun J, Chen J, Wang L, Li A, Helm M, Dubovsky SL, Bacanu SA, Zhao Z, Chen X. (2012) RNA-Seq analysis implicates dysregulation of the immune system in schizophrenia. BMC Genomics 13(Suppl. 8):S2.